Cyclic GMP Phosphodiesterase Inhibitors. 2. Requirement of 6-Substitution of Quinazoline Derivatives for Potent and Selective Inhibitory Activity

Journal of Medicinal Chemistry
1994.0

Abstract

We synthesized various 4-[[3,4-(methylenedioxy)benzyl]amino]quinazolines substituted at the 5- to 8-positions and evaluated their inhibitory activities toward cyclic GMP phosphodiesterase (cGMP-PDE) from porcine aorta. Monosubstitution at the 6-position was essential for the inhibitory activity, and the preferred substituents were compact and hydrophobic: methoxy (3b, IC50 = 0.23 microM), methyl (3c, 0.10 microM), chloro (3d, 0.019 microM), thiomethyl (3f, 0.031 microM), and cyano (3p, 0.090 microM) groups. Compounds 3b-d,f,p lacked inhibitory activity toward other PDE isozymes (all IC50 values > 100 microM), and their relaxing activities in porcine coronary arteries were well correlated with the inhibitory activities toward cGMP-PDE (r = 0.88, p < 0.05). One of these compounds, 3b, elevated the intracellular cGMP level in isolated porcine coronary arteries without causing any change in the cAMP level. We consider that this series of compounds dilates coronary arteries via potent and specific inhibition of cGMP-PDE.

Knowledge Graph

Similar Paper

Cyclic GMP Phosphodiesterase Inhibitors. 2. Requirement of 6-Substitution of Quinazoline Derivatives for Potent and Selective Inhibitory Activity
Journal of Medicinal Chemistry 1994.0
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-[[3,4-(methylenedioxy)benzyl]amino]-6,7,8-trimethoxyquinazoline
Journal of Medicinal Chemistry 1993.0
cAMP-dependent phosphodiesterase inhibition and SAR studies on novel 6,8-disubstituted 2-phenyl-3-(substituted benzothiazole-2-yl)-4[3H]-quinazolinone
Medicinal Chemistry Research 2009.0
Design, synthesis, and biological activity of certain quinazolinedione derivatives as potent phosphodiestrase4 inhibitors
Medicinal Chemistry Research 2012.0
2-(.beta.-Arylethylamino)- and 4-(.beta.-arylethylamino)quinazolines as phosphodiesterase inhibitors
Journal of Medicinal Chemistry 1985.0
Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones
Journal of Medicinal Chemistry 1987.0
Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction
Bioorganic &amp; Medicinal Chemistry Letters 2004.0
Design, synthesis and in vitro PDE4 inhibition activity of certain quinazolinone derivatives for treatment of asthma
Medicinal Chemistry Research 2012.0
4-(3-Chloro-4-methoxybenzyl)aminophthalazines:  Synthesis and Inhibitory Activity toward Phosphodiesterase 5
Journal of Medicinal Chemistry 2000.0
8-(3-Chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2015.0